Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 5/20 | 0.67 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.67 |
| ▸ | ITGAL | P20701 | 5/20 | 0.67 |
| ▸ | GHSR | Q92847 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29144196 | 1.00 | ITGB2 (0.67) | ITGB2ICAM1ITGALGHSRALOX15 | |
| SCHEMBL21641802 | 1.00 | ITGB2 (0.67) | ITGB2ICAM1ITGALGHSRALOX15 | |
| SCHEMBL29904257 | 1.00 | ITGB2 (0.67) | ITGB2ICAM1ITGALGHSRALOX15 | |
| SCHEMBL21641801 | 1.00 | ITGB2 (0.67) | ITGB2ICAM1ITGALGHSRALOX15 | |
| SCHEMBL31606450 | 0.97 | ITGB2 (0.68) | ITGB2ICAM1ITGALGHSRALOX15 | |
| SCHEMBL29533411 | 0.96 | GHSR (0.65) | ITGB2ICAM1ITGALGHSRACE | |
| SCHEMBL31609182 | 0.92 | GHSR (0.63) | ITGB2ICAM1ITGALGHSRACE | |
| SCHEMBL29550930 | 0.92 | GHSR (0.63) | ITGB2ICAM1ITGALGHSRACE | |
| SCHEMBL30051684 | 0.92 | GHSR (0.63) | ITGB2ICAM1ITGALGHSRACE | |
| SCHEMBL30052886 | 0.92 | GHSR (0.63) | ITGB2ICAM1ITGALGHSRACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119339933-A | Age estimation method based on multidimensional data | 中国科学院北京基因组研究所(国家生物信息中心) | 2025-01-21 | — | — | CN | claimed |
| CN-119015834-A | Carbon dioxide separation membrane and preparation method thereof | 国家能源投资集团有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| CN-114380889-A | Humanized ACE2 polypeptide retarder as well as design and synthesis method and application thereof | 中国科学院大连化学物理研究所 | 2022-04-22 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-120983601-A | Application of cyclic dipeptide in preparation of medicines for treating diseases related to damage of calcium sensitive receptor | 中国人民解放军陆军军医大学第二附属医院 | 2025-11-21 | — | — | CN | disclosed |
| EP-4613260-A1 | COMPOUNDS AND COSMETIC, DERMOCOSMETIC, COSMECEUTICAL OR PHARMACEUTICAL COMPOSITIONS FOR RELAXING MUSCLES, INCLUDING THE SKELETAL MUSCLES OF THE FACE, FOR ANTI-AGING COSMETIC ACTION, FOR REDUCING AND/OR SMOOTHING EXPRESSION LINES AND WRINKLES AND/OR FOR ANTIPERSPIRANT ACTION, USES AND METHODS | Chemyunion Ltda (BR) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| EP-4554615-A1 | PERSONALIZED LONGITUDINAL ANALYSIS OF CIRCULATING MATERIAL TO MONITOR AND ADAPT NEOANTIGEN CANCER VACCINES | Amazon Technologies, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119546333-A | Personalized longitudinal analysis of circulating material to monitor and modulate neoantigen cancer vaccines | 亚马逊科技公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119339933-A | Age estimation method based on multidimensional data | 中国科学院北京基因组研究所(国家生物信息中心) | 2025-01-21 | — | — | CN | disclosed |
| CN-117210441-A | Low-temperature salt-tolerant beta-glucosidase and application thereof in conversion of ginsenoside Rb1 | 云南师范大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-114380889-B | Humanized ACE2 polypeptide blocker and design and synthesis method and application thereof | 中国科学院大连化学物理研究所 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220370570-A1 | TREATMENT/PREVENTION OF DISEASE BY LINC COMPLEX INHIBITION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-11-24 | — | — | US | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
| CN-114380889-A | Humanized ACE2 polypeptide retarder as well as design and synthesis method and application thereof | 中国科学院大连化学物理研究所 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ITGB2 3494/4885ICAM1 2949/4885ITGAL 2468/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ITGB2 3719/4885ICAM1 2371/4885ITGAL 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.